CH451407A - Procédé de préparation de vaccins antigènes somatiques - Google Patents
Procédé de préparation de vaccins antigènes somatiquesInfo
- Publication number
- CH451407A CH451407A CH1271465A CH1271465A CH451407A CH 451407 A CH451407 A CH 451407A CH 1271465 A CH1271465 A CH 1271465A CH 1271465 A CH1271465 A CH 1271465A CH 451407 A CH451407 A CH 451407A
- Authority
- CH
- Switzerland
- Prior art keywords
- bacteria
- strains
- glycine
- vaccine
- vaccines
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 66
- 238000000034 method Methods 0.000 title claims description 19
- 239000000427 antigen Substances 0.000 title claims description 17
- 102000036639 antigens Human genes 0.000 title claims description 17
- 108091007433 antigens Proteins 0.000 title claims description 17
- 230000000392 somatic effect Effects 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 74
- 239000004471 Glycine Substances 0.000 claims description 37
- 241000894006 Bacteria Species 0.000 claims description 34
- 230000009089 cytolysis Effects 0.000 claims description 21
- 241000191940 Staphylococcus Species 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 241000193403 Clostridium Species 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 241000588653 Neisseria Species 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 241001112741 Bacillaceae Species 0.000 claims description 2
- 241000588921 Enterobacteriaceae Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- 241000192017 Micrococcaceae Species 0.000 claims description 2
- 241000588656 Neisseriaceae Species 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 4
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 208000004396 mastitis Diseases 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 241000206044 Clostridium chauvoei Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 229960001212 bacterial vaccine Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 229940124840 Streptococcal vaccine Drugs 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940124731 meningococcal vaccine Drugs 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 1
- 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 1
- 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 1
- 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006402 liver broth Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229960001266 typhoid vaccines Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39637364A | 1964-09-14 | 1964-09-14 | |
| US42013064A | 1964-12-21 | 1964-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH451407A true CH451407A (fr) | 1968-05-15 |
Family
ID=27015479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1271465A CH451407A (fr) | 1964-09-14 | 1965-09-14 | Procédé de préparation de vaccins antigènes somatiques |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2088112B2 (enrdf_load_stackoverflow) * | 1970-05-20 | 1975-01-10 | Cassenne Lab Sa | |
| AU2011265368B9 (en) * | 2004-09-22 | 2012-11-29 | Biosynexus Incorporated | Immunogenic composition |
| US20080095777A1 (en) * | 2004-09-22 | 2008-04-24 | Glaxosmithkline Biologicals S.A. | Immunogenic Composition for Use in Vaccination Against Staphylococcei |
| CN111254103B (zh) * | 2019-11-19 | 2023-06-02 | 河南省生物工程技术研究中心 | 一种非洲猪瘟基因工程疫苗高密度发酵补料培养基及发酵工艺 |
-
1965
- 1965-09-06 GB GB3803165A patent/GB1100190A/en not_active Expired
- 1965-09-06 SE SE1157965A patent/SE335780B/xx unknown
- 1965-09-08 DK DK459665A patent/DK113866B/da unknown
- 1965-09-10 DE DE19651467849 patent/DE1467849A1/de active Pending
- 1965-09-13 BE BE669561A patent/BE669561A/xx unknown
- 1965-09-13 NL NL6511898A patent/NL6511898A/xx unknown
- 1965-09-14 CH CH1271465A patent/CH451407A/fr unknown
- 1965-09-14 FR FR31399A patent/FR5488M/fr not_active Expired
- 1965-09-14 ES ES0317455A patent/ES317455A1/es not_active Expired
- 1965-09-14 JP JP5593465A patent/JPS4918206B1/ja active Pending
- 1965-09-14 AT AT?41265A patent/AT285044B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES317455A1 (es) | 1966-04-01 |
| GB1100190A (en) | 1968-01-24 |
| BE669561A (enrdf_load_stackoverflow) | 1965-12-31 |
| FR5488M (enrdf_load_stackoverflow) | 1967-10-30 |
| NL6511898A (enrdf_load_stackoverflow) | 1966-03-15 |
| DK113866B (da) | 1969-05-05 |
| SE335780B (enrdf_load_stackoverflow) | 1971-06-07 |
| AT285044B (de) | 1970-10-12 |
| JPS4918206B1 (enrdf_load_stackoverflow) | 1974-05-08 |
| DE1467849A1 (de) | 1968-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jenkin et al. | In vitro studies on the interaction between mouse peritoneal macrophages and strains of Salmonella and Escherichia coli | |
| TW403655B (en) | Novel attenuated pseudomonas aeruginosa strains | |
| EP0172212A1 (en) | Biological preparations and their use | |
| JP5249326B2 (ja) | 不活化ブドウ球菌全細胞ワクチン | |
| EP0560968B1 (fr) | Vaccin contre les infections a neisseria meningitidis | |
| JPH06501478A (ja) | ブドウ膜炎の処置 | |
| CN102238960B (zh) | 制造疫苗的方法 | |
| Kudyar et al. | Periodontal vaccine: A dream or reality | |
| CZ202394A3 (en) | Use of antigenic and/or immunoregulating material derived from mycobacterium vaccae when preparing a therapeutic substance containing such material and a pharmaceutical substance containing this material | |
| US3532790A (en) | Somatic antigen vaccines from lysed inactivated bacteria and process for producing them | |
| FR2481928A1 (fr) | Nouveaux mutants bacteriens, procede de leur production et vaccins vivants les contenant | |
| WO2001019395A1 (fr) | Compositions acellulaires immunogenes et compositions acellulaires vaccinales contre bacillus anthracis | |
| CH451407A (fr) | Procédé de préparation de vaccins antigènes somatiques | |
| CN101410135A (zh) | 免疫原性组合物 | |
| EP1095662B1 (fr) | Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite | |
| EP0051522B1 (fr) | Mutant de septicémie hémorragique virale, vaccin contenant ce mutant et procédé pour sa préparation | |
| Ørskov et al. | Studies on the significance of “Vi Antigen” in the Mechanism of Typhoid Infection in Mice | |
| JP2005519941A (ja) | 結核の管理のために有用な医薬組成物の製造方法 | |
| CN1210062C (zh) | 猪红斑丹毒丝菌抗原及其疫苗组合物 | |
| RU2190424C1 (ru) | Антигенный состав чумной химической вакцины | |
| RU2098128C1 (ru) | Ассоциированная вакцина "овикон" против инфекционных заболеваний конечностей овец | |
| Pollitzer | Plague studies: 2. The plague bacillus | |
| EP1628683B1 (fr) | Composition vaccinale comprenant du phosphate de fer a titre d' adjuvant vaccinal | |
| FR2652266A1 (fr) | Vaccin protecteur contre l'hemophilose porcine. | |
| EP0088302A2 (fr) | Neurotoxine de E.coli détoxifiée, procédé pour la préparer et compositions immunologiques la contenant |